drug development Latest News

Delegates now have the option to choose from 3 moderated breakout discussion groups at this conference that is set for February 21-23, San Francisco, CA (part of CHI's Molecular Med TRI-CON 2012).

Espicom Limited’s new report “Evolution in the Pain Therapy Drugs Market : Nociceptive and Neuropathic Drug Development” is now available at ReportsnReports.com.

Cambridge Healthtech Institute's 8th Annual Translational Science Event Only 7 Weeks Away! Advance Registration Discount expires Friday, January 13th!

Kalorama Information’s new report “Outsourcing in Drug Development: The Contract Research (Clinical Trials) Market” is now available at ReportsnReports.com.

Paediatric vaccine development: Some key clinical trials - their design, execution and ethics

Integration Creates Seamless Data Management and Analysis Capability for ARA Customers

Business Monitor International ‘s “Global Clinical Trial Market (2007 - 2010) (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)” is now available at ReportsnReports.com.

New award at DDL22 recognises the contribution of young people to the pharmaceutical industry.

IQPC’s 7th Annual Compound Management & Integrity Summit brings together Pharmaceutical Professionals, Clinical Research Organizations and Industry Experts to address evolving industry concerns

Holders of the IND for new products i.e. the Sponsors. Also, Principal Investigators and sub investigators, Clinical Research Scientists Safety Nurses, Clinical Research Associates and Coordinators , Recruiting staff, QA / QC auditors and staff.

SMi Group is proud to announce its 10th annual Clinical Trials in CNS conference, which will be held in London on 23rd & 24th November 2011.

IQPC’s Pharmacovigilance North America Summit brings together industry experts to address top industry concerns

Biobanking - Collaborating for Global R&D and Investment 11th & 12th July 2011 Crowne Plaza - The City, London, UK

Niiki Pharma will present Phase I clinical study data for its transferrin targeted ruthenium based anti-cancer compound, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL.

Galera Therapeutics today announced Dr. Robert (Al) Beardsley as its new Chief Executive Officer.

The Boston-area formulation development CRO Integral BioSystems, LLC announces tradeshow presence at key pharmaceutical and biotech conferences, as part of its strategy to increase visibility.

Cambridge Healthtech Institute announces two of the largest molecular imaging societies are sponsoring its In Vivo Molecular Imaging in Drug Discovery & Development event on June 8 – 9, in Philadelphia, as part of its World Pharma Congress.

Alliance combines innovative exploratory study design, leading in silico drug development capabilities, and a global licensing network to increase the value of emerging company portfolios and address pipeline gaps for established drug manufacturers.

Discuss with top the 50 pharma companies how to manage various types of pain through drugs and the development of new promising drugs from conception to clinical testing.

Regulatory options for generics through different licensing possibilities and regulatory chalenges while working in MENA will be discussed by top 50 pharma companies

75 Speaker presentations are available on CD from Cambridge Healthtech Institute’s past event, SCOPE: Summit for Clinical Ops Executives, which took place on February 7-9, 2011 in Miami, FL.

BioAtla and Charles River have partnered to create an integrated biological service for antibodies and other protein therapeutics designed to accelerate drug development for customers from the earliest stages of discovery all the way through IND.

With biobank collections increasing in value by medical researchers and drug developers worldwide, the biobank market is enjoying rapid growth in the number of national biobanks and efforts to build co-operative networks between them globally.

Identify the key issues responsible for the low success rates in CNS drug discovery and development, to highlight strategies being developed to overcome these issues and to discuss how these may change the landscape for drug development.

Company Leasing New Office Space, Increasing Workforce

Ensuring a Cohesive Scientific and Business Approach to Early-Phase Clinical Research to Ensure the Development of Safe & Effective New Therapies

Nuclear Receptors: The Pipeline Outlook Report

Therapeutic antibodies are central to pharmaceutical development; needless to say, emphasis is continually on developing new methods and improving those already in place. Play an active role in the war against disease – register online today!

This workshop will look at how to negotiate the pharmaceutical minefield that is the counterfeit threat, how to identify what will really work for you and your brand and how to stay one step ahead of the counterfeiters.

In line with its premium on quality, speed and thoroughness for its drug development services, UPM Pharmaceuticals keeps its technology up-to-date. Its most recent acquisition improves the company's pharmaceutical powder processing.

UPM Pharmaceuticals, the drug development expert, has been providing its invaluable services to the pharmaceutical industry for more than a decade. The company maintains a state-of-the-art manufacturing facility in Baltimore.

UPM Pharmaceuticals is a recognized leader in the drug development industry. The company leverages its expertise to assist pharmaceutical clients with all concerns related to medicine development.

This masterclass will examine the solubility and supersaturation of drugs from a solution chemistry point of view. We will explain how solubility is affected by molecular structure, pH, pKa and salt formation, and discuss the role of lipophilicity.

10th September 2010, Millenium Gloucester Hotel, London, UK A CPD accredited SMi Pharma-Masterclass focusing on various issues concerning Data Management in Medical Imaging

Attend this CPD Accredited Masterclass to get a better understanding of the application of epigenetic profiling to pharmaceutical development. Appreciating the potential of such techniques could result in brilliant advances in life saving technology.

The drug industry continues to face consent decrees and enforcement actions. In a free webcast on July 22 at 11 AM ET, former FDA scientist Ali Afnan and a panel of experts explore why pharma's quality systems are failing to evolve, and solutions.

MarketResearch.com has added a new report, “Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures,” which focuses on current melanoma issues and developing treatment methods.

Leading drug industry experts speak on tweaking Toyota methods to improve laboratory cycle time and efficiency.

The drug development process is a costly, thorough, and very complicated series of tasks that could all go down the drain if not monitored properly. Thankfully, UPM Pharmaceuticals assist their clients in every step.

UPM Pharmaceuticals provides drug development services including formulation development, GMP manufacturing, and stability testing. The company embodies scientific superiority and display flexibility, receptiveness, and originality.

Michael Rosenberg, founder of adaptive-focused CRO, will discuss how flexible clinical operations support the new FDA Draft Guidance on adaptive design.

Drug Delivery Technology announces a uniquely effective marketing opportunitiy offered for pharmaceutical, biotech, medical device and drug development companies in 2010.

The San Jose BioCenter Announces an Important Event on Investigational New Drug Applications via Webinar as Well as Face-to-Face

Ponsus Pharma signs an exclusive product distribution agreement with Vitaflo Scandinavia AB for Proderm Hud in Sweden, Denmark, Finland and Norway

Why do so many pharma tech transfer projects fail? How can one ensure their success? Two experts weigh in on how to do tech transfer right.

Speid & Associates is a regulatory affairs and drug development consultancy. They have recently commenced offering a new series of service offerings to European companies.

Kalos Therapeutics announced today that the Company and the scientific inventor of its exclusively licensed technology to develop a family of heart hormones, a new therapy for the treatment of cancer, was featured today on Good Morning America.

Company to enable turn-key strategic drug development approach to program management for one-stop drug, diagnostic and device development solutions - worldwide.

Ponsus Pharma recruits Mats Silvander, Ph.D. as Research & Development Manager and Dan Johansson, M.Sc. as Sales & Marketing Manager

A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of common diseases